このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Thorne HealthTech 将来の成長

Future 基準チェック /46

Thorne HealthTechは、57.2%と19.8%でそれぞれ年率57.2%で利益と収益が成長すると予測される一方、EPSはgrowで56.6%年率。

主要情報

57.2%

収益成長率

56.6%

EPS成長率

Personal Products 収益成長	23.9%
収益成長率	19.8%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	16 Oct 2023

今後の成長に関する最新情報

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Aug 12

Recent updates

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Aug 12

Thorne HealthTech swings to Q2 Non-GAAP loss per share, revenue down Y/Y, FY22 guidance revised

Aug 09

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Jun 05

Shareholders Can Be Confident That Thorne HealthTech's (NASDAQ:THRN) Earnings Are High Quality

Mar 23

Thorne HealthTech: Good Potential At A Low Price

Jan 11

業績と収益の成長予測

NasdaqGS:THRN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	418	68	65	72	2
12/31/2024	363	34	61	68	3
12/31/2023	288	16	17	47	2
6/30/2023	258	20	-15	22	N/A
3/31/2023	240	10	-25	4	N/A
12/31/2022	229	16	-13	5	N/A
9/30/2022	216	6	-14	-6	N/A
6/30/2022	206	3	-5	1	N/A
3/31/2022	194	9	-11	-4	N/A
12/31/2021	184	4	4	9	N/A
9/30/2021	172	-1	8	12	N/A
6/30/2021	162	-1	9	12	N/A
3/31/2021	150	-3	20	23	N/A
12/31/2020	138	-3	15	17	N/A
12/31/2019	103	-22	-11	-8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: THRNの予測収益成長率 (年間57.2% ) は貯蓄率 ( 2.2% ) を上回っています。

収益対市場: THRNの収益 ( 57.2% ) はUS市場 ( 14.7% ) よりも速いペースで成長すると予測されています。

高成長収益: THRNの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: THRNの収益 ( 19.8% ) US市場 ( 8.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: THRNの収益 ( 19.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: THRNの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Thorne HealthTech 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Price target increased by 11% to US$8.36

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Thorne Healthtech, Inc. Provides Earnings Guidance for 2023

Price target increased by 8.7% to US$7.50

Thorne HealthTech, Inc. Reaffirms Financial Guidance for the Full-Year 2023

Price target decreased to US$7.50

Recent updates

Thorne Appoints Mary Beech as Chief Growth Officer

Thorne Healthtech, Inc. Files Form 15

Thorne HealthTech, Inc.(NasdaqGS:THRN) dropped from NASDAQ Composite Index

Thorne HealthTech's Common Stock To Be Delisted from Nasdaq Global Select Market

Thorne HealthTech Receives Non-Compliance Notice from Nasdaq

Price target increased by 11% to US$8.36

Thorne Healthtech, Inc. Announces Resignation of Takeshi Minakata from the Board of Directors

Investor sentiment improves as stock rises 27%

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Thorne Healthtech, Inc. Provides Earnings Guidance for 2023

Thorne HealthTech, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target increased by 8.7% to US$7.50

Thorne HealthTech Reportedly Working with Bank to Explore Sale

Investor sentiment improves as stock rises 17%

Thorne HealthTech, Inc. (NASDAQ:THRN) Not Flying Under The Radar

First quarter 2023 earnings: EPS misses analyst expectations

Thorne HealthTech, Inc. Reaffirms Financial Guidance for the Full-Year 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thorne HealthTech, Inc. (NasdaqGS:THRN) acquired PreCon Health, Inc. from Eigenlyfe LLC for $5 million.

Investor sentiment improves as stock rises 15%

Thorne HealthTech, Inc. Announces Executive Changes

Investors Will Want Thorne HealthTech's (NASDAQ:THRN) Growth In ROCE To Persist

Investor sentiment improved over the past week

Thorne Healthtech's OneDraw Device Used in Department of Defense's Cancer Moonshot 2.0 Project, Prometheus, as Part of President Biden Initiative

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$7.50

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Thorne HealthTech, Inc. Revises Net Sales Guidance for the Full Year 2022

Thorne HealthTech, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Thorne HealthTech Grows But Faces Macro Headwinds

Thorne Healthtech's OneDraw(TM) Blood Collection Device Receives PMDA Certification in Japan

Thorne HealthTech's blood collection device OneDraw gets clearance in Japan

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Thorne HealthTech, Inc. Revises Sales Guidance for the Full-Year 2022

Thorne HealthTech swings to Q2 Non-GAAP loss per share, revenue down Y/Y, FY22 guidance revised

Investor sentiment improved over the past week

Thorne HealthTech, Inc. Achieves Self-Affirmed GRAS Status for Nicotinamide Riboside Malate Product

Thorne HealthTech, Inc.(NasdaqGS:THRN) dropped from Russell 2500 Value Index

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Thorne HealthTech, Inc. Relaunches Gut Health Test

Thorne HealthTech, Inc. Relaunches Gut Health Test

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Thorne HealthTech, Inc. Reaffirms Sales Guidance for the Full-Year 2022

Thorne HealthTech, Inc., Annual General Meeting, Jun 02, 2022

Co-Founder exercised options to buy US$326k worth of stock.

Consensus forecasts updated

Shareholders Can Be Confident That Thorne HealthTech's (NASDAQ:THRN) Earnings Are High Quality

Full year 2021 earnings: EPS misses analyst expectations

Thorne HealthTech: Good Potential At A Low Price

Forecast breakeven date pushed back to 2022

Forecast to breakeven in 2021

Thorne HealthTech, Inc. has completed an IPO in the amount of $70 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘